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Abstract: Diabetic nephropathy (DN) is a major microvascular complication of diabetes. Obesity
and hyperlipidemia, fueled by unhealthy food habits, are risk factors to glomerular filtration rate
(GFR) decline and DN progression. Several studies recommend that diabetic patients should be
screened early (in prediabetes) for kidney disease, in order to prevent advanced stages, for whom
the current interventions are clearly inefficient. This ambition greatly depends on the existence of
accurate early biomarkers and novel molecular targets, which only may arise with a more thorough
knowledge of disease pathophysiology. We used a rat model of prediabetes induced by 23 weeks of
high-sugar/high-fat (HSuHF) diet to characterize the phenotype of early renal dysfunction and injury.
When compared with the control animals, HSuHF-treated rats displayed a metabolic phenotype
compatible with obese prediabetes, displaying impaired glucose tolerance and insulin sensitivity,
along with hypertriglyceridemia, and lipid peroxidation. Despite unchanged creatinine levels, the
prediabetic animals presented glomerular crescent-like lesions, accompanied by increased kidney
Oil-Red-O staining, triglycerides content and mRNA expression of IL-6 and iNOS. This model of
HSuHF-induced prediabetes can be a useful tool to study early features of DN, namely crescent-like
lesions, an early signature that deserves in-depth elucidation.
Keywords: prediabetes; nephropathy; rat model; diet-induced; renal lipidosis; glomerular
crescent-like lesions
1. Introduction
According to estimates of the International Diabetes Federation (IDF), the prevalence of type 2
diabetes mellitus (T2DM) will continue to grow for decades to come in many world regions, as well
as its serious complications, including diabetic nephropathy (DN), which affects around one-third of
patients with diabetes, imposing major socio-economic costs [1,2].
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Although T2DM evolves slowly and silently until diagnosis, it progressively affects the
microvasculature, including the kidney tissue [3,4]. Glomerular hypertrophy, a modest expansion of
mesangial matrix, and thickening of glomerular capillary walls are the main features of the initial stages
of DN, then evolving to a phenotype of glomerulosclerosis, fueled by thickening of glomerular basement
membrane (GBM), mesangial cell expansion and loss of podocyte, along with tubulointerstitial fibrosis,
reduction of glomerular filtration rate (GFR), and albuminuria [5]. Unfortunately, despite the great
scientific advances, the current panoply of glucose-lowering drugs has been clearly insufficient to
hinder diabetic microvascular complications, including DN [6,7]. Thus, early identification (and
intervention) of diabetic patients with renal impairment is urgently needed.
Prediabetes, also termed intermediate hyperglycemia, has been recognized as a risk factor for the
development of both T2DM and DN [8–10]. It has been strongly suggested that people with prediabetes
should be early screened for kidney disease [11]. However, this mission is certainly very challenging
since the classical markers of kidney function, namely serum creatinine and GFR, are influenced by
several factors that bias the interpretation, as well as because they might remain unchanged until a
high proportion (around 50%) of nephrons become nonfunctional [12,13]. This is a very important
concern that has sparked much research in recent years, in order to better characterize the phenotype
of initial DN and to identify not only early biomarkers but also putative targets for timely therapeutic
intervention, which is a clear unmet clinical need [14]. For this purpose, animal models are a privileged
tool with great utility.
Great progress was made during the last two decades to develop better animal models of DN,
namely as a result of the major advances in genetic manipulation. Monogenic or polygenic mice
models can recapitulate important features of the human pathology, namely when combined with other
drivers of disease progression, including the use of (i) streptozotocin (or other toxins) to accelerate
diabetes due to promotion of beta-cell damage; (ii) hypercaloric diets (sugar- and/or fat-based); (iii)
nephrectomy strategies to reduce kidney mass and aggravate the renal decline and development of
lesions (as previously reviewed [15–17]). However, no single model is able to present all the functional
and structural changes of the human DN [18] and to accomplish the 3 criteria defined in 2003 by
the “Animal Models of Diabetic Complications Consortium (AMDCC)” for DN models [19]. Despite
the unequivocal utility of genetic models, they present relevant limitations, including the difficulty
to obtain, feed and breed, the prolonged modeling cycle, together with the complete loss of gene
expression that is rarely observed in human disease [20,21]. Therefore, animal models induced by
dietary modifications have become popular, both in rat and mouse [22–26], because they are based
on a major risk factor for the human disease: unhealthy food habits. Hypercaloric dietary regimens
are chief promotors of obesity and hyperlipidemia, which exacerbate the risk of GFR decline and DN
progression [27–30]. In addition, evidence supports the existence of abnormal deposition of lipids in
the kidney (renal lipidosis) in patients with early stage DN [31], which might promote an inflammatory
response that seems to play a key role in the onset and progression of DN [32]. However, the impact of
this deposition on markers of renal function and on the histomorphological phenotype of early renal
disease remain to be clearly elucidated, namely in the stage of prediabetes. In this study, we used
a rat model with prediabetes induced by high sugar and high fat (HSuHF) diet to characterize the
phenotype of early renal dysfunction.
2. Methods
2.1. Animals and Experimental Design
Male Wistar rats (eight-week-old; Charles River Laboratories, Barcelona, Spain) were housed two
per cage in the animal facility of Coimbra Institute for Clinical and Biomedical Research (iCBR), Faculty
of Medicine, University of Coimbra, and were maintained under controlled temperature (22 ± 1 ◦C),
relative humidity (50–60%) and a 12-h light/dark cycle conditions. All procedures involving animals
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were performed according to the National and European Communities Council Directives of Animal
Care. The project received approval (9/2018) by the local (iCBR) Animal Welfare Body (ORBEA).
After an adaptation period of 1 week, rats were randomly divided into two groups (n = 8 each,
2 animals per cage) and submitted to a 23-weeks protocol: Control group—received standard rat chow
(total 3.15 kcal−1—8.6% of energy as fat, 67.9% as carbohydrates, 23.5% as protein; 4RF21 Mucedola,
Milan, Italy) and tap water; HSuHF group—received 35% sucrose (Hsu-84100; Sigma-Aldrich, Saint
Louis, Missouri, USA) in the drinking water plus standard chow until week 9, further supplemented
by High Fat diet (HF, total 5.10 kcal g−1—61.6% of energy as fat, 20.3% as carbohydrates and 18.1% as
protein; 58Y1, TestDiet) until week 23.
Animals consumed food and water ad libitum (except during fasting periods). Body weight
(BW) measurements were obtained weekly using an analytical balance (CQT 2000 Core® Portable
Compact Balance, Adam Equipment, Oxford, CT, USA) and food and liquid consumption were also
monitored weekly.
2.2. Blood and Tissues Collection
The day before finishing the experiment (at week 23), rats were submitted to an intraperitoneal
anesthesia with a 2 mg/kg BW of a 50 mg/kg pentobarbital (Sigma-Aldrich, Saint Louis, Missouri, USA)
solution and a blood sample was instantly collected by venipuncture from the jugular vein into syringes
(for serum samples collection). Thereafter, the rats were sacrificed by cervical dislocation and kidneys
were immediately collected, weighed and divided, and stored according to further analysis: prefixed
in a 10% neutral buffered formalin solution for histopathological analysis or cryopreserved in liquid
nitrogen for triglycerides content and lipid peroxidation assays, protein and gene expression analysis.
2.3. Metabolic Characterization
2.3.1. Glycemic Profile
Fasting and fed glycemia: Blood glucose levels at fasting (assessed after 6-h of fasting, performed
between 8:00 and 14:00) and under fed conditions were measured in the sacrifice day from a drop of
blood collected by venipuncture in the jugular vein with the aid of the Accu-Chek® Aviva glucometer
(Roche, Mannheim, Germany).
Hemoglobin A1C (HbA1c) was measured on the day of sacrifice through a drop of blood placed
on an automated analyzer (Siemens, DCA Vantage Analyzer TM, Tarrytown, NY, USA).
Glucose tolerance test (GTT): In the first day of the last treatment week (23), rats were administered
intraperitoneally with a glucose bolus of 2 g/kg BW following a 6-h fasting period. Blood glucose
levels were quantified through the tail vein before the injection and 15, 30, 45 and 60 min after, using
the portable device Accu-Chek® Aviva glucometer (Roche, Mannheim, Germany). The area under the
curve (AUC) for the GTT was calculated by using the trapezoidal method, as previously described [23].
2.3.2. Insulinemic Profile
Fasting and fed insulin: Insulin levels were measured in serum samples (in fed and 6-h
fasting conditions, performed between 8:00 and 14:00) by using a rat insulin ELISA (Enzyme-Linked
Immuno-Sorbent Assay) kit from Mercodia (Uppsala, Sweden).
Insulin tolerance test (ITT): In the last day of the last treatment week (23), rats were administered
intraperitoneally with insulin (0.75 U/kg BW, Actrapid Novo Nordisk) following a 6-h fasting period.
Blood glucose levels were obtained through a drop of blood from the tail vein before the bolus and 30,
60 and 120 min after, using the portable device Accu-Chek® Aviva glucometer (Roche, Mannheim,
Germany). The area under the curve (AUC) for the ITT was calculated by using the trapezoidal method,
as previously described [24].
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2.3.3. Lipidic Profile
At the end of the in vivo protocol, blood was collected into syringes without anticoagulant and
centrifuged (35,000 rpm, 15 min at 4 ◦C). Total cholesterol and TG levels were assessed in serum using
an automated analyzer (Hitachi 717, Roche Diagnostics, Mannheim, Germany) that makes use of
Cholesterol RTU reagent and kit TG PAP 1000 (bioMérieux, Lyon, France) for the measurement of
cholesterol and TGs, respectively, by colorimetric methods.
2.4. Serum Markers of Redox Status and Inflammation
Serum redox status was assessed by the thiobarbituric acid reactive species (TBARs) assay,
measuring lipid peroxidation via malondialdehyde (MDA) content, and by the total antioxidant
status (TAS) quantification, through ferric reducing antioxidant potential (FRAP) assay, as previously
described [33]. High sensitivity C-reactive protein (hs-CRP) levels in serum were measured by using a
rat-specific Elisa kit (MBS764381, MyBiosource, San Diego, CA, USA).
2.5. Renal Function Data
2.5.1. Serum Biochemical Parameters
The following biochemical parameters were evaluated in serum by validated automated methods
and equipment (Hitachi 717, Roche Diagnostics, Mannheim, Germany): creatinine, uric acid, and blood
urea nitrogen (BUN).
2.5.2. 24-h Urine Parameters
During week 23, animals were housed in metabolic cages for 24 h, receiving water and food ad
libitum. Urinary creatinine, BUN and uric acid concentrations were evaluated in 24-h urine (Cobas
Integra 400 plus, Roche Diagnostics, Mannheim, Germany), and urine volumes were measured to
calculate clearances, according to what was previously described [34].
2.6. Renal Histomorphology
2.6.1. Hematoxylin and Eosin (H&E) Staining
Renal tissue samples were formalin-fixed and embedded in paraffin wax. Cryosections (5 µm)
from each block were reviewed. Briefly, tissue sections were deparaffinized in xylene and hydrated to
a decrescent series of ethanol until distilled water. Thereafter, the tissue sections were immersed in
hematoxylin stain Solution, Gill 1 (Sigma Aldrich, Saint Louis, MO, USA) for 2 min and washed in
tap water. Then, they were counterstained with 0.5% aqueous eosin (Sigma Aldrich; MO, USA) for
30 s and after that dehydrated, cleared, and mounted. All samples from both groups (n = 8 for each)
were examined by light microscopy using a Zeiss microscope Mod. Axioplan 2 (Göttingen, Germany).
The degree of injury visible by light microscopy was scored in the total tissue on the slide, focusing
glomerular (100 glomeruli per experimental condition), tubulointerstitial and vascular lesions.
2.6.2. Periodic Acid of Shiff (PAS) and PAS-Diastase Staining
For PAS staining, tissue sections were deparaffinized in xylene and hydrated to a decrescent series
of ethanol until distilled water. Then, they were treated with periodic acid (Sigma Aldrich, Saint Louis,
MO, USA) for 5 min and rinsed in distilled water. After that they were stained with Schiff’s reagent
(Sigma Aldrich, Saint Louis, MO, USA) for 10 min and washed in tap water for 3 min. Nuclei were
counterstained with hematoxylin stain Solution, Gill 1 (Sigma Aldrich, Saint Louis, MO, USA) for
1 min and rinsed in tap water. Tissue sections are then dehydrated cleared and mounted.
For Pas-Diastase, tissue sections were deparaffinized in xylene and hydrated to a decrescent
series of ethanol until distilled water. Then, they were treated with 0.5% amylase solution (Sigma
Aldrich, Saint Louis, MO, USA) for 15 min and washed in running tap water followed by periodic
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acid incubation (Sigma Aldrich, Saint Louis, MO, USA) for 5 min and rinsed in distilled water. After
that they were stained with Schiff’s reagent (Sigma Aldrich, Saint Louis, MO, USA) for 10 min and
washed in tap water for 3 min. Nuclei were counterstained with hematoxylin stain Solution Gill 1
(Sigma Aldrich, Saint Louis, MO, USA) for 1 min and rinsed in tap water. Tissue sections were then
dehydrated cleared and mounted. All samples were examined by light microscopy using a Zeiss
microscope Mod. Axioplan 2 (Göttingen, Germany).
2.6.3. Gomori’s Green Trichrome Staining
Tissue sections were deparaffinized in xylene and hydrated to a decrescent series of ethanol until
distilled water. Then the slides were treated with Weigert’s iron hematoxylin (Sigma Aldrich, Saint
Louis, MO, USA) stain from 7 min. Slides were placed into Chromotrope 2R (Sigma Aldrich, Saint
Louis, MO, USA) at 0.2% with Light green at 0.8% solution for 5 min. Then, a quickly rinse off the stain
with distilled water was performed and then differentiated with acetic acid at 0.5%. Tissue sections
were then dehydrated, cleared, and mounted. The cytoplasm of the cells was stained in red, fibrin in
pink whereas collagen was observed in green, in contrast with blue or black nuclei. All samples were
examined by light microscopy using a Zeiss microscope Mod. Axioplan 2 (Göttingen, Germany)
2.6.4. Collagen IV Immunohistochemistry
Renal sections (7 µm in thickness) were cut in a cryostat (Leica CM3050S, Nussloch, Germany),
mounted directly onto SuperFrost Plus microscope slides (Menzel-Glaser, Thermo Fisher Scientific,
Braunschweig, Germany) and stored at −80 ◦C until use. Renal sections were air dried for at least
30 min at room temperature (RT) and then fixed in cold acetone:methanol (1:1) for 10 min. After
washing with phosphate-buffered saline (PBS: 137 mM NaCl, 27 mM KCl, 81 mM Na2HPO4, 15 mM
KH2PO4, pH 7.3, 3 × 5 min), sections were permeabilized for 15 min with 0.5% Triton X-100 in PBS
and blocked with 3% BSA in PBS for 40 min. Sections were incubated overnight at 4 ◦C with primary
antibody: anti- collagen IV (1:250, ab19808-Abcam), diluted in PBS with 0.3% BSA. After rinsing with
PBS, slices were incubated with secondary fluorescent antibody Alexa Fluor 488-conjugated goat
anti-Rabbit (1:200; AB029488—SICGEN) and with 4′,6-diamidino-2-phenylindole (DAPI) for 1 h at RT
in a humidified chamber in the dark. Samples were washed with PBS (3 × 5 min), mounted using the
glycergel mouting medium (Dako North America, Inc, Carpinteria, CA, USA) and sealed with nail
polish. The samples were stored at 4 ◦C until acquisition of images in the confocal microscope (LSM
710, Carl Zeiss, Göttingen, Germany). For a negative experiment, the primary antibody was omitted.
2.6.5. Ki-67 Immunostaining
Tissue sections were deparaffinized in xylene and hydrated to a decrescent series of ethanol
until distilled water. Antigen retrieval was performed using high pH target retrieval solution (Dako,
Glostrup, Denmark) in a PTLink module (Dako) for 20 min at 96 ◦C. Slides were then treated with
an endogenous-peroxidase blocking solution (S2023; Dako) followed by a protein blocking solution
(X0909; Dako) and the primary antibody at 1:1000: anti-Ki-67 Ab, MIB-5, (Dako M7248). The reaction
was detected using the HRP labelled polymer (DakoCytomation) and revealed with diaminobenzidine
(DAB) chromogen DakoCytomation).
2.7. Renal Lipid Deposition
2.7.1. Oil Red O Staining
Tissue sections of fresh frozen tissue were cut to 5 µm thickness, mounted on slides and allowed
to dry for 30 min. The cryosections were placed in absolute propylene glycol for 2 min and transferred
to 0.5% red oil in absolute propylene glycol solution for 10 min. The sections were differentiated in 85%
propylene glycol solution for 2 min, washed in distilled water and counterstained in Hematoxylin Stain
Solution Gill 1 (Sigma Aldrich, Saint Louis, MO, USA) for 30 s. They were rinsed under running water
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for 3 min and mounted with CC / Mount aqueous mounting medium (Sigma Aldrich, Saint Louis, MO,
USA). The lipids were stained with bright red color and nuclei with a blue color. All samples were
examined by light microscopy using a Zeiss microscope Mod. Axioplan 2.
2.7.2. Kidney Triglycerides Levels
Triglycerides contents on kidney samples were measured by an enzymatic colorimetric assay
using a commercial kit (Ref.1155010, Triglycerides MR, Cromatest ®, Linear Chemicals, Barcelona,
Spain). Briefly, 50 mg of frozen tissue were homogenized in 1 mL of isopropanol. The homogenate
was sonicated and then centrifuged at 3000 rpm for 5 min at 4 ◦C, and the supernatant was analysed
following the manufacter’s instructions.
2.8. Kidney Gene and Protein Expression
2.8.1. qRT-PCR Gene Expression Analysis
50 mg from frozen renal tissue (stored in RNA later™ solution, ThermoFisher) were processed
with a Trizol protocol (93289, Sigma).and stored overnight at −80 ◦C. Total amount of RNA extracted,
RNA integrity (RIN, RNAIntegrity Number) and purity (A260/A280) were measured by Nano Chip®
kit in Agilent 2100 Bioanalyzer (2100 expert software, Agilent Technologies, Walbronn, Germany) and
ND-1000® spectrophotometer (NanoDrop Tecnhologies, Wilmington, DE, USA), respectively. cDNA
was synthesized using a Xpert cDNA Synthesis Mastermix (GK81.0100, Lot. 7E2709A, GRISP, Porto,
Portugal) according to the manufacter’s instructions.
For each PCR reaction, 20 µL volume was used containing 2 µL of cDNA, 10 µL of Sybr
Green (iTaq Universal SYBR Green Supermix 1725124, Bio-Rad, Hercules, CA, USA), 0.4 µL of each
primer (listed in Table 1) and 7.6 µL of autoclaved DEPC water. Gene expression was normalized with
GeNorm algorithm, where gene stability was attained with glyceraldehyde 3-phosphate dehydrogenase
(GAPDH) and hypoxanthine-guanine phosphoribosyltransferase (HPRT). The relative expression ratio
of each of the target gene was computed on the basis of ∆∆Ct (2−∆∆Cp) values.
Table 1. Primer sequence used for the RT-PCR analysis.
Gene Forward Primer Sequence Reverse T (◦C)
iNOS AGAGACAGAAGTGCGATC AGATTCAGTAGTCCACAATAGTA 60
IL-6 GGAGAAGTTAGAGTCACAGA GCCGAGTAGACCTCATAG 60
TNF-α CCCAATCTGTGTCCTTCT TTCTGAGCATCGTAGTTGT 60
GAPDH GACTTCAACAGCAACTCC GCCATATTCATTGTCATACCA 60
HPRT ATGGGAGGCCATCACATTGT ATGTAATCCAGCAGGTCAGCAA 58
2.8.2. Protein Content Analysis by Western Blotting
Kidneys were weighed (150–200 mg) and homogenized in ice-cold Radio Immuno Precipitation
Assay (RIPA) buffer. Thereafter, samples were centrifuged at 13,200 rpm for 15 min at 4 ◦C and protein
concentration was determined using the bicinchoninic acid (BCA) protein assay kit (PierceTM BCA,
Pierce Biotechnology, Rockford, IL, USA).
An equal amount of denatured proteins were separated using 7.5%–15% sodium dodecyl sulfate
polyacrylamide gel electrophoresis (SDS-PAGE), and electrophoretically transferred to 0.45 µm
polyvinylidene difluoride (PVDF) membrane (Amersham™Hybond™, GE Healthcare Life Sciences,
Freiburg, Germany) as previously described [35]. Membranes were incubated overnight at 4 ◦C with
primary antibodies (listed on Table 2) diluted in 1% milk/ 0.1% PBS-T followed by the incubation with
adequate secondary antibodies (Table 2) diluted in 1% milk/ 0.1% PBS-T with agitation for 1 h at room
temperature (RT). Finally, membranes were visualized on ImageQuant™LAS500 (GE Healthcare Life
Sciences) and optical density of the bands was quantified using Image Quant TL 5.0. software (GE
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healthcare–Life Sciences, Life Sciences, Freiburg, Germany). Results were normalized against internal
controls tubulin or anti-β-actin antibodies and then expressed as percentage of control.
Table 2. Primary and secondary antibodies used for Western Blotting analysis.





Goat anti-mouse IgG-HRP 1:10,000 R-05071-Advansta
Goat anti-rabbit IgG-HRP 1:10,000 R-05072-Advansta
2.9. Statistical Analysis
Results were expressed as means± standard errors of the mean (S.E.M.) and % of the Control,
as indicated, using GraphPad Prism® software, version 8.0.1 (GraphPad Software, Inc., La Jolla, CA,
USA). Comparisons between groups were analyzed by Student’s t-test for normally distributed data or
the Mann Whitney test for non-normally distributed data. Differences were considered to be significant
at p < 0.05.
3. Results
3.1. Body Weight, Caloric Intake and Glycemic and Insulinemic Profile
Body weight at the beginning of the study was identical between groups. The variation (delta) of
BW during the entire treatment was significantly higher (p < 0.05) in the HSuHF-treated rats (Table 3).
Even though HSuHF-treated animals ingested significantly more liquid and less solid food, a higher
total caloric intake was achieved (p < 0.001 for all), which was mainly obtained from carbohydrates
and lipids. In opposition, the caloric intake obtained from proteins was lower in the prediabetic
animals (Table 3). Despite no significant changes between groups on fasting glucose and insulin
levels, there were increased values in the HSuHF-treated animals in fed conditions (p < 0.001 and
p < 0.05, respectively), accompanied by impaired GTT and ITT (Figure 1), as viewed by the significantly
increased AUCs (Table 3).
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Table 3. Body weight, caloric intake and glycemic and insulinemic profile.
Parameters Control HSuHF
Body Weight (BW)
Initial (g) 300.00 ± 10.88 297.11 ± 9.71
Final (g) 507.57 ± 18.15 578.62 ± 32.89
Delta BW (g) 228.50 ± 10.04 311.20 ± 21.11*
Caloric Data
Food Intake (g/week) 163.60 ± 2.20 77.11 ± 0.54 ***
Beverage Intake (mL/week) 211.80 ± 3.69 326.70 ± 50.89 ***
Calories from Carbohydrates (kcal/rat/week) 350.40 ± 3.89 574.50 ± 13.84 ***
Calories from Lipids (kcal/rat/week) 44.22 ± 0.47 97.74 ± 8.71
Calories from Proteins (kcal/rat/week) 121.20 ± 1.29 51.68 ± 1.60 ***∑
Total calories (kcal/rat/week) 515.80 ± 5.49 713.40 ± 10.17 ***
Glycemic Profile
Fasting glucose(mg/dL) 100.50 ± 1.37 115.77 ± 1.42
Fed glucose (mg/dL) 149.14 ± 7.95 273.14 ± 33.53 ***
GTT (AUC) 31856 ± 2565 54974.2 ± 3413 ***
HbA1c (%) 3.73 ± 0.05 4.00 ± 0.15
Insulinemic Profile
Fasting insulin (µg/L) 0.577 ± 0.082 1.454 ± 0.197
Fed insulin (µg/L) 0.899 ± 0.159 2.426 ± 0.535 *
ITT (AUC) 8107 ± 299 11175 ± 587 **
Values are means ± S.E.M. of n = 8 per group. * P < 0.05; ** P < 0.01 and *** P < 0.001.
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3.3. Kidney Histomorphology  
To evaluate the presence (and nature) of glomerular and tubulointerstitial lesions, kidney 
sections were stained with H&E, PAS, and Gomori staining (Figure 2 and Figure S1). The general 
observation using H&E staining with 10x magnification suggested the existence of glomerular lesions 
in the HSuHF animals, without changes of tubulointerstitial structures, when compared with the 
control kidneys (data not shown), despite the presence of focal inflammatory infiltrate in 2 out of 8 
of the HSuHF-fed animals (Figure 2C), located in the tubular interstitial compartment of renal 
Figure 1. In vivo glucose tolerance test (A) and insulin tolerance test (B) at the end of the study in the
Control and HSuHF-treated rats. Values are means ± S.E.M. of n = 8 per group. * P < 0.05; ** P < 0.01,
*** P < 0.001 and **** P < 0.0001.
3.2. Renal Function Data
There was a trend toward reduced kidney weight (KW)/BW ratio in the prediabetic animals versus
the control (Table 4). There were no differences between groups regarding serum and urine measures of
creatinine and uric acid, as well as concerning their clearances. However, serum and urine BUN levels
were significantly decreased (p < 0.001) in the HSuHF-treated rats versus the control ones, as well as
clearance (p < 0.01) (Table 4).
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Table 4. Kidney weight and serum and urine measures of renal function.
Parameters Control HSuHF
Kidney Weight (KW)
Absolute (g) 2.86 ± 0.13 2.90 ± 0.12
KW/BW (g/kg) 5.63 ± 0.22 4.92 ± 0.07
Creatinine
Serum (mg/dL) 0.36 ± 0.01 0.38 ± 0.02
Urine (mg/dL) 100.40 ± 14.78 61.15 ± 7.84
Clearance (mL/h) 200.40 ± 18.55 184.4 ± 11.57
BUN
Serum (mg/dL) 14.19 ± 0.58 8.57 ± 0.60 ***
Urine (mg/dL) 1554.00 ± 132.80 493.00 ± 82.90 ***
Clearance (mL/h) 92.53 ± 7.24 35.59 ± 4.29 **
Uric Acid
Serum (mg/dL) 1.79 ± 0.33 2.33 ± 0.52
Urine (mg/dL) 12.80 ± 1.74 9.86 ± 0.69
Clearance (mL/h) 6.50 ± 1.10 6.00 ± 1.02
Values are means ± S.E.M. of n = 8 per group. ** P < 0.01 and *** P < 0.001.
3.3. Kidney Histomorphology
To evaluate the presence (and nature) of glomerular and tubulointerstitial lesions, kidney sections
were stained with H&E, PAS, and Gomori staining (Figure 2 and Figure S1). The general observation
using H&E staining with 10x magnification suggested the existence of glomerular lesions in the
HSuHF animals, without changes of tubulointerstitial structures, when compared with the control
kidneys (data not shown), despite the presence of focal inflammatory infiltrate in 2 out of 8 of the
HSuHF-fed animals (Figure 2C), located in the tubular interstitial compartment of renal medulla,
without signs of interstitial fibrosis and tubular atrophy (IFTA) (Figure 2J–L). The glomerular lesions
were further confirmed by using 40x magnification, including thickening of the GBM and mesangial
expansion (Figure 2B,C), without glomerular atrophy or glomerulosclerosis, except in one animal
of the HSuHF group, most probably more prone to hypercaloric diet (data not shown because were
not the most representative lesions). Surprisingly, we found an atypical pattern of extracapillary
hyperplasia of glomerular capsule parietal layer surrounding and compressing Bowman’s space in
about 20% of the glomeruli of all prediabetic animals, and no more than one per glomerulus (Figure 2B,C
and Supplementary Figure S1). These crescent-like structures were even more clearly represented
through PAS staining (Figure 2E,F and Supplementary Figure S1), further confirming the existence of
focal inflammatory infiltrate, thickening of the GBM and mesangial expansion (Figure 2E,F) in the
HSuHF-fed animals.
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Figure 2. Representative images of glomerular (A–I) and tubulointerstitial (J–L) regions and lesions
in the Control and HSuHF-treated rats (n = 8 per group) evaluate by H&E, PAS and Gomori staining
(all with 40× amplification). Arrows represent the glomerular lesions better identified in the above
description of results: 1) the presence of glomerular crescent-like structures; 2) mesangial expansion; 3)
thickening of the GBM; 4) focal inflammatory infiltrate.
Gomori staining was unable to show clear evidence of fibrosis in both the Control and HSuHF-fed
rats, neither in glomeruli (Figure 2G–I) nor in tubulointerstitial region (Figure 2J–L). This was
further confirmed with collagen type IV staining (Figure 3). This type of collagen, particularly the
conformations α1, α2, and α6, are normally present in Bowman’s capsule. As expected, Bowman’s
capsule was markedly stained as well as the tubular basement membrane and the mesangial matrix [36].
Nonetheless there were no changes between the two groups regarding to the intensity of staining and
the integrity of internal glomerular structures. Furthermore, no obvious signs of Bowman’s capsule
disruption in renal sections from HSuHF, compared to the control animals, were observed (Figure 3).
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To provide an in-depth analysis of crescent-like structures, kidney sections were stained with
Ki-67, a classical marker of proliferation (Figure 4). Considering that Ki-67 is crucial for progression of
cell division cycle, the absent of staining observed in both glomerular section of control and HSuHF
animals (Figure 4) appears to indicate that the renal cells are in the resting state G0. Furthermore, the
use of a positive Control (HuH-7 cells, a hepatocellular carcinoma cell line) was essential to corroborate
the presence of Ki-67 during mitotic phases.
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Figure 4. Representative images of Ki-67 immunostaining in the Control (B and E) and HSuHF-treated
(C and F) rats (n = 8 per group). Huh7 cell line was used as a positive control (A and D). A–C: 10×;
D–F: 100×). * Crescent-like structure in the HSuHF rats.
3.4. Serum and Renal Lipids
There was an increased lipid deposition in the renal tissue of the prediabetic rats, versus the
control ones, as viewed by the increased staining with Oil-Red O (Figure 5A–D). The increased lipid
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deposition was viewed in all the 8 animals of the HSuHF group, and was evident in both renal cortex
and medulla. This effect was coherently accompanied by a significantly (p < 0.05) increased contents of
TGs, both in renal tissue and serum (Figure 5G). In addition, a trend to higher kidney MDA content
and a significantly (p < 0.05) increased serum MDA/TAS ratio was observed in the HSuHF-treated
animals (Figure 5H).
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3.5. Serum and Renal Inflammatory Markers
There were no changes between groups for serum hs-CRP levels (Figure 6A). However, there
was an increased renal expression of IL-6 and iNOS mRNA in the HSuHF-treated animals versus the
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control ones (Figure 6B,C), without changes of iNOS protein expression (Figure 6D) and TNF-α mRNA
and protein expression (Figure 6E,F).
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Figure 6. Serum hs-CRP levels (A) and kidney expression of IL-6 mRN (B), iNOS mRNA (C) and
protein (D), as well as TNF-α mRNA (E) and protein (F) expression in the Control and HSuHF-treated
rats. Values are means ± S.E.M. of n = 8 per group (except for western blotting: n = 6 per group), and
were expressed as relative expression (for mRNA) in relation to two housekeeping genes used (GAPDH
and HPRT) and as % of control (for protein). * P < 0.05.
4. Discussion
T2DM is the most common cause of chronic kidney disease (CKD) and end stage renal disease
(ESRD) worldwide [37]. DN, a long-term major microvascular complication of T1DM a d T2DM,
affects a large population in the United States and Western Europe, where arou d one-third of diabetic
individuals have nephropathy [38].
Currently existing therapeutic approaches do not allow reversing or controlling the kidney
disease in i termediate stages, being clearly ineffective, nd trace patients in advanced stages for
transplantation or dialysis. This inability to cope with the disease imposes high socio-economic costs
that clearly require more effective and, above all, earlier measures. However, for this to become a
reality, two conditions are crucial: -on the one hand, finding early markers, more reliable than those
currently existing; -on the other, discovering molecular targets for possible therapeutic approaches,
namely for the development of new drugs targeting the mechanisms of disease at the kidney level and
not only the associated conditions, such as hyperglycemia and hyperlipidemia [6,7]. The scientific
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knowledge required often demands studies on animal models. It is well recognized, namely by studies
in humans, that changes in renal function might start many years before the diagnosis of diabetes,
in a prediabetic stage [9,10]. However, much remains to be known regarding the precise phenotype
of DN in the prediabetes phase, with a clear lack of information on animal models. In this work,
we used a prediabetes rat model induced by a high calorie diet to characterize the phenotype of this
early nephropathy.
Male Wistar rats under a hypercaloric diet for 23 weeks showed metabolic features compatible
with obese prediabetes. In fact, despite fasting normoglycemia, the HFD-treated rats presented
fed hyperglycemia and hyperinsulinemia, with glucose intolerance and reduced insulin sensitivity.
Additionally, the animals showed hypertriglyceridemia and increased serum oxidative stress, without
changes in hs-CRP. This profile is in line with other studies performed in rats under HFD [22,39].
Concerning renal function, the prediabetic animals showed unchanged values of serum, urine
and clearance of creatinine and uric acid, despite reduced BUN values which could be explained by the
reduced protein consumption when compared with the control animals. These results are in agreement
with other studies in Wistar rats under longstanding HFD that were unable to show marked changes
on renal function markers [40]. The absence of changes in creatinine until a significant part of the
glomeruli is already affected (it is estimated about 50%) is a known fact that has been portrayed as a
limitation of the classic markers of renal function assessment, strongly recommending better markers
of early renal dysfunction [12,13].
Regarding the histomorphological characterization, no significant tubulointerstitial lesions were
observed, despite the presence of focal inflammatory infiltrate in 2 out of 8 of the HsuHF-fed animals,
located in the tubular interstitial compartment of renal medulla, without signs of IFTA. However,
we found the existence of several glomerular lesions, including mesangial expansion and thickening
of the GBM, without atrophy or glomerulosclerosis (except in one animal), which collectively is in
agreement with other models in initial stages of nephropathy [22]. Remarkably, we found an atypical
pattern of extracapillary hyperplasia of glomerular capsule parietal layer surrounding and compressing
Bowman’s space in about 20% of the glomeruli of all prediabetic animals. These lesions, resembling
crescent-like structures, are a well-known pathological component of glomerulonephritis, affecting
nearly 50% of overall glomerular circumference [41,42]. Yet, glomerular crescents development within
diabetic kidney disease (DKD) has also been reported and is envisaged as a regular feature of glomerular
changes within diabetes, although the available information is largely limited to the examination of
human biopsies [43–47]. It is important to highlight that renal biopsies in diabetes are reserved for
patients with atypical presentations in routinely clinical practice. Thus, qualitative and quantitative
renal morphology information of human diabetic glomerular injuries greatly involve an intrinsic
selection bias, reinforcing the importance of preclinical assessment of DKD through reliable animal
models [45,48,49]. Interestingly, a linkage between diabetic glomerulopathy and crescent-like structures
has already been pinpointed in Zucker diabetic fatty (ZDF) rats, a genetic T2DM animal model widely
used in the preclinical setting as they spontaneously develop insulin resistance and obesity at a young
age and progressively develop hyperglycemia and renal injury [20,50,51]. Remarkably, extracapillary
hyperplasia within glomerular capsule was observed in nearly 30% of glomeruli of young ZDF rats (7
weeks old) displaying glucose intolerance (although still normoglycemic) and impaired renal function
(increased urinary protein/creatinine ratio). An aggravation of the metabolic status until overt diabetes
(week 20) was accompanied by a progressive deterioration of renal function along with glomerular
histopathological features comprising increased crescent-like structures in Bowman’s parietal layer
(≈44%) [52]. Likewise, we here report glomerular crescent-like structures paralleling impaired renal
function in a diet-induced animal model of prediabetes without overt hyperglycemia. Crescents
have been classically defined as any proliferative or fibrous space within parietal layer of Bowman’s
space [47]. Even though the precise pathogenesis of crescents‘ formation is unknown, two types are
generally recognized: inflammatory crescents and pseudocrescents. An elegant work from Gaut et al.
(2014) provided valuable evidence of the nature of cells forming crescents in diabetes, composed mainly
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by parietal epithelial cells (PEC’s) and podocytes within the parietal layer of glomerular capsule without
GBM rupture, an ultrastructural alteration that is typically observed in inflammatory crescents [53].
These authors postulate that within DKD, pseudocrescents are the most likely scenario. In an attempt
to evaluate the nature of these lesions in our experimental setting, we started to assess fibrotic features
through the classical Gomori’s Green Trichrome staining. We were unable to visualize evident signs
of extracellular matrix accumulation, mainly composed by proteoglycans, fibronectin and fibrillar
collagen [54]. Since trichrome stains is often unreliable at milder levels of fibrosis [55], we further
analyze conformational determinants on collagen type IV, normally used to demarcate Bowman’s
capsule in renal tissues [56]. Consistent with the lack of glomerular sclerotic lesions in our previous
histological analysis, there were no evident signs of collagen IV structural reorganization. We proceed
with the identification of proliferating cellular subpopulations through Ki-67 immunohistochemistry.
Cells express Ki-67 antigen during S, G2 and M phases while it is undetectable at quiescent stages [57,58].
The lack of Ki-67 staining hints for a post-proliferating quiescent state of cellular crescentic components
at the time point of our study. Future studies, namely in earlier time-points and using alternative
markers of proliferation (e.g., BrdU), are warranted to unequivocally conclude the proliferating nature
of crescents as well as their cellular composition.
The varied terminology used to describe these structures (crescents, pseudocrescents, extracapillary
hypercellularity) clearly shows that their origin, biology, and pathophysiological implications remain
doubtful and should be further elucidated [46,47]. Among the various hypotheses that have been
suggested to explain the pathophysiological role of pseudocrescents, the one that seems to be more
relevant is that these structures may represent a potentially beneficial response to the insult. Briefly,
it has been described that PECs may have the capacity to act as progenitor cells for injured podocytes
and migrate from Bowman’s capsule to the capillary tuft in response to injury. This ability has been
envisaged as an attempt of the injured glomerulus to heal itself and counteract the ongoing injury
through podocytes repopulation [46,53]. In our model, hyperglycemia or hyperlipidemia induced by
HSuHF diet might be the driven forces for the metabolic damage (via glucotoxicity and lipotoxicity)
underlying the formation of psudocrescents. Despite the absence of a clear inflammatory phenotype,
at both systemic and renal levels, the existence of oxidative stress and renal lipidosis might explain
the renal damage, as previously suggested by others [59,60]. These possibilities are in line with the
association between obesity/adiposity and increased risk of GFR decline and mortality in individuals
with and without CKD [27]. Renal damage induced by lipotoxicity is a complex process that has been
progressively disclosed [60,61]. The increased renal expression of IL-6, regardless of normal serum
hs-CRP, might be linked to hyperglycemic and hyperlipidemic stimuli, as previously suggested [62,63].
It has becoming clear that changes in renal lipid metabolism promote ectopic lipid deposition in
the kidney tissue, which contributes to nephropathy. In fact, para-perirenal distribution of fat was
associated with reduced GFR, which might occur via distinct mechanisms, including by adverse effects
caused by increased leptin availability or free-fatty acids migration into the kidney, leading to renal
lipidosis, as well as by direct mechanical compression of renal vessels and parenchyma with subsequent
reduced renal blood flow [59]. Further studies should focus on the elucidation of the precise role of
lipid deposition within the renal tissue for the evolution of renal damage and the early appearance of
pseudocrescents. In any case, PEC’s hyperplasia co-expressing kidney injury molecule-1 expression
have been associated with progressive podocytopenia in diabetic rats [52]. Moreover, crescent-like
lesions have been identified as a novel poor prognostic indicator of time from DKD to ESRD [46].
5. Conclusions and Future Directions
We here presented a new rat model of hypercaloric diet-induced prediabetes with renal damage.
Such a model may provide a valuable tool to evaluate early features of DN and disclose new predictors
of disease progression, with focus on crescent-like lesions, which are an early signature that deserves
in-depth elucidation regarding their origin, biology, and pathophysiological implications. Overall,
it will be paramount in future studies to early identify them and elucidate the molecular mechanisms
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that govern their appearance and growth, in order to find approaches that enhance their putative
endogenous repair ability before a condition of exhaustion occurs, after which nephropathy might
progress to advanced chronic stages. Specifically, it will be important to clarify the cell composition
of crescents, namely using molecular markers for different cell types, including PECs (e.g., PAX-2,
PAX-8, cytokeratin), podocytes (e.g., synaptopodin, VEGF, CD36) and/or GBM (e.g., claudin-1) [64].
Furthermore, the impact of lipid accumulation in renal structures for the development of renal disease,
namely as inductor of inflammatory markers (such as IL-6), should be further elucidated. The precise
determination of lipids (including non-esterified fatty acids) accumulated in glomeruli and tubules
will be potentially relevant to better characterize the renal disease at this stage of prediabetes.
Despite the possible disadvantages of this model of nephropathy in a condition of prediabetes,
namely the long-lasting (23 weeks) feeding with a hypercaloric diet, which is associated with a
significant expenditure of human and financial resources when compared with genetic models with
fast development of DN, significant advantages exist. In fact, the hypercaloric diet may be suspended
at any time throughout treatment, thus allowing testing the possibility of renal disease reversal, which
open up the possibility to study therapeutic strategies targeting kidney recovering. However, further
studies are required to evaluate intermediate time-points and better characterize the evolution of kidney
dysfunction and lesions during the progression of prediabetes. Additional topics for future work
include the evaluation of female rats in order to confirm or deny sex susceptibility to this phenotype,
as has been suggested in other models.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6643/12/4/881/s1,
Figure S1: Images of glomerular crescent-like structures (depicted with arrows) evaluated by H&E, PAS and
Gomori staining in the HSuHF-treated rats.
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